FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

State-of-the-art gene therapy provides new treatment option for children 2 years and older with life-threatening blood disorder

State-of-the-art gene therapy provides new treatment option for children 2 years and older with life-threatening blood disorder